Effectiveness of antiviral treatment on acute phase of herpes zoster and development of post herpetic neuralgia: Review of international publications

Medecine et Maladies Infectieuses

Volumn 42, Issue 2, 2012, Pages 53-58

  Bruxelle, J ^a   Pinchinat, S ^b  

^a FONDATION OPHTALMOLOGIQUE ADOLPHE DE ROTHSCHILD   (France)

^b Axonal Biostatem   (France)

Author keywords

Acute herpes zoster pain; Antiviral drugs; Herpes zoster; Post herpetic neuralgia

Indexed keywords

ACICLOVIR; FAMCICLOVIR; PLACEBO; VALACICLOVIR;

ACUTE DISEASE; ANALGESIA; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ATTITUDE TO ILLNESS; COST EFFECTIVENESS ANALYSIS; DISEASE DURATION; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG SAFETY; HEADACHE; HERPES ZOSTER; HUMAN; IMMUNOCOMPROMISED PATIENT; NAUSEA; NONHUMAN; PAIN ASSESSMENT; PATIENT COMPLIANCE; POSTHERPETIC NEURALGIA; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; THERAPY DELAY; VESICULAR RASH; VIRUS REPLICATION;

2-AMINOPURINE; ACUTE DISEASE; ACYCLOVIR; AGE FACTORS; AGED; ANTIVIRAL AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; EARLY DIAGNOSIS; HERPES ZOSTER; HUMANS; META-ANALYSIS AS TOPIC; MIDDLE AGED; NEURALGIA, POSTHERPETIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VALINE; WORLD HEALTH;

EID: 84856620638     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2011.11.001     Document Type: Review

References (54)

1. Johnson R.W., Whitton T.L. Management of herpes zoster (shingles) and post herpetic neuralgia. Expert Opin Pharmacother 2004, 5:551-559.
2. Dworkin R.H., Johnson R.W., Breuer J., et al. Recommendations for the management of herpes zoster. Clin Infect Dis 2007, 44:S1-S26.
3. Lancaster T., Silagy C., Gray S. Primary care management of acute herpes zoster: systematic review of evidence from randomized controlled trials. Br J Gen Pract 1995, 45:39-45.
4. Johnson R., Patrick D. Improving the management of varicella herpes zoster and zoster-associated pain. Recommendations from the IHMF management strategies workshop. Int Herpes Manag Forum 2002, 1-111.
5. McKendrick M.W., McGill J.I., White J.E., Wood M.J. Oral acyclovir in acute herpes zoster. BMJ 1986, 293:1529-1532.
6. Volpi A., Gross G., Hercogova J., Johnson R.W. Current management of herpes zoster: the European view. Am J Clin Dermatol 2005, 6:317-325.
7. NHS quality improvement Scotland. Evidence note 21: antiviral treatment for shingles and its complications in immunocompetent adults, 2008.
8. Tyring S., Barbarash R.A., Nahlik J.E., et al. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia: a randomized, double-blind placebo-controlled trial. Ann Intern Med 1995, 123:89-96.
9. Simpson D., Lyseng-Williamson K.A. Famciclovir: a review of its use in herpes zoster and genital and orolabial herpes. Drugs 2006, 66:2397-2416.
10. Cirelli R., Herne K., McCrary M., Lee P., Tyring S.K. Famciclovir: review of clinical efficacy and safety. Antiviral Res 1996, 29:141-151.
11. Degreef H. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. Int J Antimicrob Agents 1994, 4:241-246.
12. Shafran S.D., Tyring S.K., Ashton R., et al. Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. J Clin Virol 2004, 29:248-253.
13. Tyring S.K., Beutner K.R., Tucker B.A., Anderson W.C., Crooks R.J. Antiviral therapy for herpes zoster. Randomized controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. Arch Fam Med 2000, 9:869.
14. Saltzman R., Jurewicz R., Boon R. Safety of famciclovir in patients with herpes zoster and genital herpes. Antimicrob Agents Chemother 1994, 38:2454-2457.
15. Shen M.C., Lin H.H., Lee S.S., et al. Double-blind, randomized, acyclovir-controlled, parallel-group trial comparing the safety and efficacy of famciclovir and acyclovir in patients with uncomplicated herpes zoster. J Microbiol Immunol Infect 2004, 37:75-81.
16. Chakrabarty A., Tyring S.K., Beutner K., Rauser M. Recent clinical experience with famciclovir-a " third generation" nucleoside produg. Antivir Chem Chemother 2004, 15:251-253.
17. Lilie H.M., Wassilew S. The role on antivirals in the management of neuropathic pain in the older patient with herpes zoster. Drugs Aging 2003, 20:561-570.
18. Lin W.T., Lin H.H., Lee S.S.J., et al. Comparative study of the efficacy and safety of valaciclovir versus acyclovir in the treatment of herpes zoster. J Microbiol Immunol Infect 2001, 34:138-142.
19. Beutner K.R., Friedman D.J., Forszpaniak C., Andersen P.L., Wood M.J. Valaciclovir compared with acyclovir for improved therapy for herpes zoster in immunocompetent adults. Antimicrob Agents Chemother 1995, 39:1546-1553.
20. Wassilew S.W., Wutzler P. Oral brivudin in comparison with acyclovir for herpes zoster: a survey study on postherpetic neuralgia. Antiviral Res 2003, 59:57-60. Brivudin Herpes Zoster Study Group.
21. Johnson R.W. Herpes zoster and postherpetic neuralgia: a review of the effects of vaccination. Aging Clin Exp Res 2009, 21:236-243.
22. Schmader K. Herpes zoster and postherpetic neuralgia in older adults. Clin Geriatr Med 2007, 23:632.
23. Wareham D., Breuer J. Herpes Zoster. BMJ 2007, 334:1211-1215.
24. Tyring S.K. Management of herpes zoster and postherpetic neuralgia. J Am Acad Dermatol 2007, 57:s136-s142.
25. Schmader K.E., Dworkin R.H. Natural history and treatment of herpes zoster. J Pain 2008, 9:s3-s9.
26. Cunningham A.L., Breuer J., Dwyer D.E., et al. The prevention and management of herpes zoster. Med J Aust 2008, 188:171-176.
27. Johnson R.W., Dworkin R.H. Treatment of herpes zoster and postherpetic neuralgia. BMJ 2003, 326:748-750.
28. Dworkin R.H., Schmader K.E. Treatment and prevention of postherpetic neuralgia. Clin Infect Dis 2003, 36:877-882.
29. Wood M.J., Ogan P., McKendrick M.W. Efficacy of oral acyclovir treatment of acute herpes zoster. Am J Med 1988, 85:79-83.
30. Harding S.P., Porter S.M. Oral acyclovir in herpes zoster ophthalmicus. Curr Eye Res 1991, 10:93-95.
31. Huff J.C., Bean B., Balfour H.H. Therapy of herpes zoster with oral acyclovir. Am J Med 1988, 85:84-89.
32. Morton P., Thomson A.N. Oral acyclovir in the treatment of herpes zoster in general practice. N Z Med J 1989, 102:93-95.
33. Wood M.J., Kay R., Dworkin R.H. Oral acyclovir therapy accelerates pain resolution in patients with herpes zoster: a meta-analysis of placebo controlled trials. Clin Infect Dis 1996, 22:341-347.
34. Crooks R.J., Jones D.A., Fiddian A.P. Zoster-associated chronic pain: an overview of clinical trials with acyclovir. Scand J Infect Dis Suppl 1991, 80:62-68.
35. Alper S.B., Lewis P.R. Does treatment of acute herpes zoster prevent or shorten postherpetic neuralgia? A systematic review of the literature. J Fam Pract 2000, 49:255-264.
36. Opstelten W., Eekhof J., Neven A.K., Verheij T. Treatment of herpes zoster. Can Fam Physician 2008, 54:373-377.
37. Huff J.C., Drucker J.L., Clemmer A. Effect of oral acyclovir on pain resolution in herpes zoster: a reanalysis. J Med Virol 1993, Supplement 1:93-96.
38. Whitley R.J., Weiss H., Gwann J.W. Acyclovir with and without prednisone for the treatment of herpes zoster. A randomized, placebo-controlled trial. Ann Intern Med 1996, 125:376-383.
39. Jackson J.L., Gibbons R., Meyer G., Inouye L. The effect of treating herpes zoster with oral acyclovir in preventing postherpetic neuralgia. Arch Int Med 1997, 157:909-912.
40. Li Q., Chen N., Yang J., et al. Antiviral treatment for preventing postherpetic neuralgia. The Cochrane collaboration 2009, John Wiley and Sons Ltd.
41. Dworkin R.H., Boon R.J., Grinffin D.R., Postherpetic Neuralgia: Impact of famciclovir, age, rash severity, and acute pain in herpes zoster patients. J Infect Dis 1998, 178:S76-S80.
42. Mick G., Gallais J.L., Simon F., et al. Burden of Herpes Zoster and postherpetic neuralgia: incidence, proportion, and associated costs in the French population aged 50 or over. Rev Epidemiol Sante Publique 2010, 58:393-401.
43. Segarra-Newnham M., Tagoff S.S. Valacyclovir and postherpetic neuralgia. J Pharm Technol 2004, 20:229-232.
44. Partridge D.G., McKendrick M.W. The treatment of varicella-zoster virus infection and its complications. Expert Opin Pharmacother 2009, 10:797-812.
45. Gnann J.W., Whitley R.J. Herpes Zoster. N Engl J Med 2002, 347:340-346.
46. Johnson R.W. Pain following herpes zoster: implications for management. Herpes 2004, 11:63-65.
47. Wood M.J., Shukla S., Fiddian A.P., Crooks R.J. Treatment of acute herpes zoster: effect of early (<48h) versus Late (48-72h) therapy with acyclovir and valaciclovir. J Infect Dis 1998, 178:S81-S84.
48. Decroix J., Partsch H., Gonzalez R., et al. Factors influencing pain outcome in herpes zoster: an observational study with valaciclovir. J Eur Acad Dermatol Venereol 2000, 14:23-33.
49. Kurokawa I., Kumano K., Murakawa K. Clinical correlates of prolonged pain in Japanese patients with acute herpes zoster. J Int Med Res 2002, 30:56-65. and the Hyogo Prefectural PHN study group.
50. Johnson R.W. Herpes zoster in the immunocompetent patient: management of post-herpetic neuralgia. Herpes 2003, 10:38-45.
51. Zhou M., Zhou D., He L. Postherpetic neuralgia in herpes zoster. J Am Med Assoc 2009, 302:1862-1863.
52. Harpaz R., Ortega-Sanchez I., Seward J., Advisory Committee on Immunization Practices (ACIP), Centers for Disease Control Prevention (CDC) Prevention of herpes zoster: recommendations of the advisory committee on immunization practices (ACIP). MMWR Recomm Rep 2008, 57(RR-5):1-30.
53. Wood MJ, Kroon S. Reducing the burden of Zoster-associated pain. Int Herpes Manag Forum, 1997.
54. Kempf W., Meylan P., Gerber M., et al. Swiss recommendations for the management of varicella zoster virus infections. Swiss Med Wkly 2007, 137:239-251.